



(12) Translation of
European patent specification

(11) NO/EP 3886852 B1

NORWAY

(19) NO

(51) Int Cl.

A61K 31/216 (2006.01)

A61K 31/192 (2006.01)

A61K 31/41 (2006.01)

A61K 31/439 (2006.01)

A61K 31/56 (2006.01)

A61K 31/59 (2006.01)

A61K 31/7048 (2006.01)

A61P 27/02 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2024.06.03
(80)	Date of The European Patent Office Publication of the Granted Patent	2024.01.31
(86)	European Application Nr.	18942199.3
(86)	European Filing Date	2018.12.03
(87)	The European Application's Publication Date	2021.10.06
(84)	Designated Contracting States:	AL; AT; BE; BG; CH; CY; CZ; DE; DK; EE; ES; FI; FR; GB; GR; HR; HU; IE; IS; IT; LI; LT; LU; LV; MC; MK; MT; NL; NO; PL; PT; RO; RS; SE; SI; SK; SM; TR
(73)	Proprietor	Smilebiotek Zhuhai Limited, Room 103, Building 1, 36 Doukou Road Traditional Chinese Medicine Science and Technology Industrial Park of Co-operation between Guangdong and Macao Hengqin New Area, Zhuhai City, Guangdong Province, Kina
(72)	Inventor	WEI, Lai, No. 2522 Huandao North Road, Hengqin New District, Zhuhai, Guangdong 519000, Kina OUYANG, Hui, No. 2522 Huandao North Road, Hengqin New District, Zhuhai, Guangdong 519000, Kina ZHANG, Yan, No. 2522 Huandao North Road, Hengqin New District, Zhuhai, Guangdong 519000, Kina
(74)	Agent or Attorney	Murgitroyd & Company, Mannerheimvägen 12 B, 5tr, 00100 HELSINGFORS, Finland

(54)	Title	OCTYL GALLATE AND ESTERS THEREOF OF FOR USE IN THE TREATMENT AND PREVENTION OF AGE-RELATED MACULAR DEGENERATION CAUSED BY BACILLUS MEGATERIUM
(56)	References Cited:	WO-A1-2016/090005, WO-A1-2020/098630, US-B1- 6 218 368, US-A1- 2014 328 951, WO-A2-2007/029008, CN-A- 1 436 074, CN-A- 1 731 997, CN-A- 101 137 370, CN-A- 102 558 178, CN-A- 108 349 867, CN-A- 109 706 238, JP-A- 2014 094 917, JP-B2- 6 036 193, KR-A- 20120 041 390, KR-B1- 101 706 389, US-A1- 2009 082 470, KANG JUNG-HWAN ET AL: "Protective effects of resveratrol and its analogs on age-related macular degeneration in vitro", ARCHIVES OF PHARMACAL RESEARCH, NATL. FISHERIES UNIVERSITY , PUSAN, KR, vol. 39, no. 12, 22 September 2016 (2016-09-22), pages 1703- 1715, XP036121196, ISSN: 0253-6269, DOI: 10.1007/S12272-016-0839-0 [retrieved on 2016- 09-22] XIAOFENG WEN ET AL: "Epigenetics, microbiota, and intraocular inflammation: New paradigms of immune regulation in the eye", PROGRESS IN RETINAL AND EYE RESEARCH, vol. 64, 1 May 2018 (2018-05-01), pages 84-95, XP055707633, GB ISSN: 1350-9462, DOI: 10.1016/j.preteyeres.2018.01.001 Yu Feifei; Sun He: "Recent research status of traditional Chinese medicine on age-related macular degeneration", National Medical Frontiers of China, Chinese Hospital Association, vol. 3, no. 16, 31 August 2008 (2008-08-31), pages 13-14,41, XP009521638, CN ISSN: 1673-5552

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

PATENTKRAV

1. Terapeutisk virksom mengde av en forbindelse 9
eller et farmasøytisk aksepterbart salt eller en farmasøytisk akseptierbar ester derav,
5 eller en farmasøytisk sammensetning som omfatter forbindelsen eller det farmasøytisk
aksepterbare salt eller den farmasøytisk aksepterbare ester derav, for anvendelse i
behandling eller forebygging av aldersrelatert makuladegenerasjon (AMD), som videre
omfatter å identifisere eller ha identifisert subjektet som værende infisert med en
mikroorganisme i det intraokulære rom, hvor mikroorganismen omfatter *Bacillus*
10 *megaterium*,

